Literature DB >> 23296120

External validation of the updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection.

Mauro Gacci1, Riccardo Schiavina, Michele Lanciotti, Lorenzo Masieri, Sergio Serni, Valerio Vagnoni, Firas Abdollah, Marco Carini, Giuseppe Martorana, Francesco Montorsi.   

Abstract

INTRODUCTION: The aim of our study was to determine the validity of the updated nomogram [Briganti et al.: Eur Urol 2012;61:480-487] as a prediction tool for pelvic lymph node invasion (LNI) in the current era by using a large multicentric population of men who underwent extended pelvic lymph node dissection (ePLND) at the time of radical prostatectomy (RP) at tertiary referral centers. PATIENTS AND METHODS: Between 2000 and 2011, 896 consecutive patients underwent RP and ePLND at two tertiary referral centers for clinically localized prostate cancer (PCa). Uni- and multivariable logistic regression models predicting the presence of LNI at ePLND were built in. Covariates consisted of preoperative PSA, clinical stage, primary and secondary biopsy Gleason grade with or without percentage of positive cores. Patients' data were entered into a logistic model formula derived from the original publication of Briganti. The nomogram was assessed by comparing its predicted probability of LNI with the actual presence of LNI. The area under the curve was used to quantify its predictive accuracy.
RESULTS: Mean preoperative PSA, clinical and pathological stage, primary and secondary biopsy and pathological Gleason grade, such as mean number of total cores, positive cores and percentage of positive cores differed significantly between LNI-positive and LNI-negative patients (all p < 0.001 except for number of total cores, p = 0.019). The mean number of lymph nodes removed was 14.8, and LNI was found in 101 patients (11.8%). In the univariate analysis the percentage of positive cores was the most accurate predictor of LNI (72%), followed by PSA (69%), primary biopsy Gleason grade (64%), clinical stage (60%), and secondary biopsy Gleason grade (59%). The predictions of the nomogram were virtually perfect when the predicted probability was ≤20%. We tested the performance characteristics of various Briganti nomogram-derived cut-offs (1-14%) for discriminating between patients with and without LNI. In our population, 41.6% of patients were classified below the 5% cut-off proposed in the original Briganti et al. report. In the multivariate analysis these variables remained statistically significant predictors for the presence of lymph node metastases. The predictive accuracy of the full model reached 79%.
CONCLUSIONS: The updated nomogram predicting LNI in patients with PCa undergoing ePLND has been externally validated, demonstrating excellent accuracy and calibration characteristics and a general applicability for predicting the presence of LNI.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2012        PMID: 23296120     DOI: 10.1159/000343993

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  6 in total

1.  Laparoscopic sentinel lymph node dissection in prostate cancer patients: the additional value depends on preoperative data.

Authors:  Caroline Rousseau; Thierry Rousseau; Cédric Mathieu; Jacques Lacoste; Eric Potiron; Geneviève Aillet; Pierre Nevoux; Georges Le Coguic; Loïc Campion; Françoise Kraeber-Bodéré
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-05-11       Impact factor: 9.236

Review 2.  Prostate cancer nomograms: a review of their use in cancer detection and treatment.

Authors:  R J Caras; Joseph R Sterbis
Journal:  Curr Urol Rep       Date:  2014-03       Impact factor: 3.092

3.  External evaluation of the Briganti nomogram to predict lymph node metastases in intermediate-risk prostate cancer patients.

Authors:  Nicolas Peilleron; Arnaud Seigneurin; Caroline Herault; Camille Verry; Michel Bolla; Jean-Jacques Rambeaud; Jean-Luc Descotes; Jean-Alexandre Long; Gaelle Fiard
Journal:  World J Urol       Date:  2020-06-24       Impact factor: 4.226

4.  Validation and head-to-head comparison of three nomograms predicting probability of lymph node invasion of prostate cancer in patients undergoing extended and/or sentinel lymph node dissection.

Authors:  Nikolaos Grivas; Esther Wit; Corinne Tillier; Erik van Muilekom; Floris Pos; Alexander Winter; Henk van der Poel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-05       Impact factor: 9.236

5.  How radical prostatectomy procedures have changed over the last 10 years in Italy: a comparative analysis based on more than 1500 patients participating in the MIRROR-SIU/LUNA and the Pros-IT CNR study.

Authors:  Mauro Gacci; Walter Artibani; Pierfrancesco Bassi; Filippo Bertoni; Sergio Bracarda; Alberto Briganti; Giorgio Carmignani; Luca Carmignani; Giario Conti; Renzo Corvò; Cosimo De Nunzio; Ferdinando Fusco; Pierpaolo Graziotti; Isabella Greco; Stefania Maggi; Stefano Maria Magrini; Vincenzo Mirone; Rodolfo Montironi; Giuseppe Morgia; Giovanni Muto; Marianna Noale; Stefano Pecoraro; Angelo Porreca; Umberto Ricardi; Elvio Russi; Giorgio Russo; Andrea Salonia; Alchiede Simonato; Sergio Serni; Davide Tomasini; Andrea Tubaro; Vittorina Zagonel; Gaetano Crepaldi
Journal:  World J Urol       Date:  2020-08-01       Impact factor: 4.226

6.  Prostate-specific antigen nadir after high-dose-rate brachytherapy predicts long-term survival outcomes in high-risk prostate cancer.

Authors:  Hideyasu Tsumura; Takefumi Satoh; Hiromichi Ishiyama; Ken-Ichi Tabata; Shouko Komori; Akane Sekiguchi; Masaomi Ikeda; Shinji Kurosaka; Tetsuo Fujita; Masashi Kitano; Kazushige Hayakawa; Masatsugu Iwamura
Journal:  J Contemp Brachytherapy       Date:  2016-04-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.